"Continue to Expect Krystexxa Label Expansion" - Oppenheimer Horizon Therapeutics (HZNP) at Outperform with $140 Price Target
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $140.00 price target on Horizon Therapeutics (NASDAQ: HZNP), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
